BEDMINSTER, NJ, December 6, 2021 (GLOBE NEWSWIRE) – Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its nanocrystal Paradigm Shifting Lipid (LNC), today announced the appointment of Thomas Hoover to the newly created position of Chief Business Officer.
Mr. Hoover’s role will include business and corporate development, strategic planning, licensing and alliance management.
“We are delighted that Thomas is joining our leadership team in this critical role during this time of transformation for our business,” commented Jerome D. Jabbour, CEO of Matinas. “Thomas’s extensive experience leading the business and corporate development functions will be invaluable as we advance our LNC platform, assess and execute collaborations with third parties, and make strategic decisions to expand our internal pipeline of LNC-based therapies. “
Mr. Hoover has nearly 20 years of strategic biopharmaceutical experience in business and enterprise development roles, as well as new product planning in a wide range of therapeutic categories including CNS, oncology, cell therapy. , autoimmune diseases, endocrinology and CV / metabolic. Thomas was most recently Chief Business Officer and Chief Commercial Officer at Millendo Therapeutics, a publicly traded biotechnology company, where he led company development efforts and defined and executed business strategy. Prior to this role, Mr. Hoover was Vice President of Corporate Development and New Product Planning for Sunovion (formerly Sepracor, Inc.). Earlier in his career, Mr. Hoover held strategic positions of increasing responsibility at GlaxoSmithKline and began his pharmaceutical career with the Boston Consulting Group.
“Matinas’ LNC technology platform has the potential to redefine the intracellular delivery of a variety of small and more complex molecules, and I am delighted to join at such an exciting time in the company’s trajectory,” Mr. Hoover said. “I look forward to partnering with Jerry and the exceptional team at Matinas in order to maximize and realize the true potential of the LNC platform. “
Mr. Hoover holds an MBA from the Kenan-Flagler Business School at the University of North Carolina and a BA in Economics from Harvard University.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutic products through its paradigm-shifting Lipid Nanocrystals (LNC) delivery platform. The Company is developing its own internal product portfolio and is partnering with leading pharmaceutical companies to develop new formulations that take full advantage of the unique characteristics of the LNC platform.
Preclinical and clinical data have demonstrated that this new technology can provide solutions to many complex challenges to achieve safe and efficient intracellular delivery, both for small molecules and for larger and more complex molecules, such as MRNA, DNA plasmids, antisense oligonucleotides and vaccines. The combination of a unique mechanism of action and flexibility in both formulation and route of administration (including oral), positions Matinas LNC technology to potentially become the delivery vehicle for Preferred new generation intracellular drug and a significant improvement over lipid and viral nanoparticles. vectors.
MAT2203 is an LNC oral formulation of amphotericin B, a highly effective but also highly toxic antifungal drug primarily used as a first-line treatment for invasive fungal infections. MAT2203 is currently in a Phase 2, open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT Cohort 3 enrollment began after unanimous approval from the Data and Safety Oversight Board (DSMB) and is now fully enrolled. The DSMB’s assessment of the data from cohort 3 and the potential progression of the cohort is expected before the end of 2021.
MAT2501 is an oral LNC formulation of the broad spectrum amikacin aminoglycoside antibiotic, primarily used to treat chronic and acute bacterial infections. With support from the Cystic Fibrosis Foundation, MAT2501 is currently undergoing major preclinical studies and began a Phase 1 human clinical trial in the fourth quarter of 2021. MAT2501 is reportedly the first and only oral aminoglycoside, and will be completed. positions with an initial indication for the treatment of non-tuberculous mycobacterial lung disease (NTM), including infections in patients with cystic fibrosis.
LYPDISO ™, is a composition based on omega-3 fatty acids available only on prescription, composed mainly of EPA and DPA, intended for the treatment of cardiovascular and metabolic disorders. This new generation omega-3 therapy has been shown in two comparative studies to effectively lower triglycerides and significantly higher blood levels of EPA than Vascepa®. The Company has initiated a process to identify and potentially find a partner to further develop LYPDISO.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to our business activities, strategy and plans, the potential of our LNC platform delivery technology and development. future of its product candidates, including MAT2203, MAT2501, the expected schedule of regulatory submissions, the expected schedule of clinical studies, the expected schedule of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if any, and the ability to obtain the required regulatory approval and other statements of a predictive nature, which depend on or refer to events or future conditions. All statements other than statements of historical fact are statements which may be forward-looking statements. Forward-looking statements include words such as “expects”, “anticipates”, “intention”, “plans”, “may”, “believes”, “believes” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from future results expressed or implied by forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to our ability to raise additional capital to meet our liquidity needs on acceptable terms, or not at all, including the additional capital that will be required to complete clinical trials of our product candidates; our ability to successfully research, develop and market our product candidates; uncertainties inherent in clinical trials; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any senior management or key personnel or consultants; competetion; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under “Risk Factors” in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company does not undertake to publish any revision of these forward-looking statements to reflect events or circumstances subsequent to the date hereof or to reflect the occurrence of unforeseen events. Matinas BioPharma’s product candidates are all in the development phase and are not available for sale or use.
Investor and media contacts
Peter Vozzo ICR Westwicke 443-213-0505 email@example.com Source: Matinas BioPharma Holdings, Inc.